Cargando…
Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program
BACKGROUND: Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these...
Autores principales: | Jacob, Suma, Anagnostou, Evdokia, Hollander, Eric, Jou, Roger, McNamara, Nora, Sikich, Linmarie, Tobe, Russell, Murphy, Declan, McCracken, James, Ashford, Elizabeth, Chatham, Christopher, Clinch, Susanne, Smith, Janice, Sanders, Kevin, Murtagh, Lorraine, Noeldeke, Jana, Veenstra-VanderWeele, Jeremy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188723/ https://www.ncbi.nlm.nih.gov/pubmed/35690870 http://dx.doi.org/10.1186/s13229-022-00505-6 |
Ejemplares similares
-
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial
por: Hollander, Eric, et al.
Publicado: (2022) -
Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder
por: Tobe, Russell, et al.
Publicado: (2023) -
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
por: McCracken, James T., et al.
Publicado: (2021) -
Translation in fragile X: no home runs in the first at-bat
por: Veenstra-VanderWeele, Jeremy
Publicado: (2017) -
Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m)
por: Beversdorf, David Q., et al.
Publicado: (2023)